Loading…

Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants

The continual emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern, in particular the newly emerged Omicron (B.1.1.529) variant and its BA.X lineages, has rendered ineffective a number of previously FDA emergency use authorized SARS-CoV-2 neutralizing antibod...

Full description

Saved in:
Bibliographic Details
Published in:Med 2022-10, Vol.3 (10), p.705-721.e11
Main Authors: Duty, J. Andrew, Kraus, Thomas, Zhou, Heyue, Zhang, Yanliang, Shaabani, Namir, Yildiz, Soner, Du, Na, Singh, Alok, Miorin, Lisa, Li, Donghui, Stegman, Karen, Ophir, Sabrina, Cao, Xia, Atanasoff, Kristina, Lim, Reyna, Mena, Ignacio, Bouvier, Nicole M., Kowdle, Shreyas, Carreño, Juan Manuel, Rivero-Nava, Laura, Raskin, Ariel, Moreno, Elena, Johnson, Sachi, Rathnasinghe, Raveen, Pai, Chin I., Kehrer, Thomas, Cabral, Elizabeth Paz, Jangra, Sonia, Healy, Laura, Singh, Gagandeep, Warang, Prajakta, Simon, Viviana, Sordillo, Emilia Mia, van Bakel, Harm, Liu, Yonghong, Sun, Weina, Kerwin, Lisa, Teijaro, John, Schotsaert, Michael, Krammer, Florian, Bresson, Damien, García-Sastre, Adolfo, Fu, Yanwen, Lee, Benhur, Powers, Colin, Moran, Thomas, Ji, Henry, Tortorella, Domenico, Allen, Robert
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The continual emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern, in particular the newly emerged Omicron (B.1.1.529) variant and its BA.X lineages, has rendered ineffective a number of previously FDA emergency use authorized SARS-CoV-2 neutralizing antibody therapies. Furthermore, those approved antibodies with neutralizing activity against Omicron BA.1 are reportedly ineffective against the subset of Omicron subvariants that contain a R346K substitution, BA.1.1, and the more recently emergent BA.2, demonstrating the continued need for discovery and characterization of candidate therapeutic antibodies with the breadth and potency of neutralizing activity required to treat newly diagnosed COVID-19 linked to recently emerged variants of concern. Following a campaign of antibody discovery based on the vaccination of Harbor H2L2 mice with defined SARS-CoV-2 spike domains, we have characterized the activity of a large collection of spike-binding antibodies and identified a lead neutralizing human IgG1 LALA antibody, STI-9167. STI-9167 has potent, broad-spectrum neutralizing activity against the current SARS-COV-2 variants of concern and retained activity against each of the tested Omicron subvariants in both pseudotype and live virus neutralization assays. Furthermore, STI-9167 nAb administered intranasally or intravenously provided protection against weight loss and reduced virus lung titers to levels below the limit of quantitation in Omicron-infected K18-hACE2 transgenic mice. With this established activity profile, a cGMP cell line has been developed and used to produce cGMP drug product intended for intravenous or intranasal use in human clinical trials. Funded by CRIPT (no. 75N93021R00014), DARPA (HR0011-19-2-0020), and NCI Seronet (U54CA260560). [Display omitted] •A neutralizing antibody retains activity across BA.1 and BA.2 subvariants•Therapeutic protection against WA-1, Delta, and Omicron pathogenesis in K18-hACE2 mice•Equivalent efficacy of i.n.- and i.v.-delivered SARS-CoV-2 neutralizing antibody therapy COVID-19 infection remains an ongoing concern for the global population, where development of new treatments remains critical as new variants emerge. Using in vitro systems and a mouse model of COVID-19 infection, researchers at Sorrento Therapeutics and Mount Sinai identified novel neutralizing antibodies that potently neutralized different variants of COVID-19 including Omicron subvariants BA.1, BA.1.1,
ISSN:2666-6340
2666-6359
2666-6340
DOI:10.1016/j.medj.2022.08.002